Market revenue in 2021 | USD 3.4 million |
Market revenue in 2032 | USD 20.4 million |
Growth rate | 17.7% (CAGR from 2021 to 2032) |
Largest segment | Chronic immunomodulators |
Fastest growing segment | Monoclonal Antibodies |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2032 |
Quantitative units | Revenue in USD million |
Market segmentation | Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy |
Key market players worldwide | AstraZeneca PLC, Grifols SA Ordinary Shares - Class A, Avadel Pharmaceuticals PLC, Novartis AG ADR, Pfizer Inc, AbbVie Inc, Roche Holding AG, GlaxoSmithKline, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to myasthenia gravis treatment market will help companies and investors design strategic landscapes.
Chronic immunomodulators was the largest segment with a revenue share of 32.35% in 2021. Horizon Databook has segmented the Mexico myasthenia gravis treatment market based on cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy covering the revenue growth of each sub-segment from 2018 to 2032.
Mexico accounted for the second-largest market share in terms of revenue in 2020. This growth can be attributed to increasing awareness about autoimmune diseases, including MG, which has led to early diagnosis and increased demand for its treatment drugs.
According to a study published by Mexican Journal of Neuroscience, in Mexico, seronegative form is very prevalent possibly owing to laboratory inconsistencies. The same source also stated that there is underutilization of immune suppressor therapies in the country and the mortality rate is high, with higher impact on elderly people.
Furthermore, rising medical tourism in Mexico due to its cost-effective healthcare services is anticipated to make Mexico the preferred destination for MG treatment, which is expected to drive the demand for novel therapeutics in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico myasthenia gravis treatment market , including forecasts for subscribers. This country databook contains high-level insights into Mexico myasthenia gravis treatment market from 2018 to 2032, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account